Jazz Pharmaceuticals (JAZZ) reported $897.84 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.5%. EPS of $1.68 for the same period compares to $2.68 a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback